Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

  title={Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial},
  author={Martin Schuler and James C. N. Yang and Keunchil Park and J.-H. Kim and Jaafar Bennouna and Y.-M. Chen and Christos Chouaid and Filippo de Marinis and J Feng and Federico V. Grossi and D.-W. Kim and Xiaoqing Liu and Shun Lu and J{\'a}nos Strausz and Yuriy Vinnyk and Rainer Wiewrodt and Caicun Zhou and B. Wang and Vikram Khub Chand and David Planchard and Sai Hong Ignatius Ou and James Chih-Hsin Yang and Klaus Rohr and Claudia In{\'e}s Bagnes and Claudio M Martin and Gonzalo Recondo and Juan Jos{\'e} Zarb{\'a} and C{\'e}sar R Blajman and Martin Eduardo Richardet and Sue-Anne Mclachlan and Phillip Parente and Craig Underhill and Catherine Crombie and Paul Mainwaring and Richard Greil and Yves Humblet and Fr{\'e}d{\'e}rique Bustin and Luciano Carestia and Danny Galdermans and Marc Emiel Celine Lambrechts and Laetitia Delval and Piet Vercauter and Jin Wang and Cheng Huang and Xiaoyan Lin and Yilong Wu and Ying Sheng Cheng and Shukui Qin and Jifeng Feng and Jianjin Huang and Yao Jun Zhang and Manuela Zereu and Bernardo Garicochea and Cyntia Albuquerque Zadra and Henrik Riska and Tuomo Alanko and Jacques Cadranel and G{\'e}rard Zalcman and Denis Moro Sibilot and Maurice P{\'e}rol and Pierre Fournel and R. A. Gervais and Maciej Rotarski and Bruno P Coudert and Michael Thomas and Thomas Wehler and Martin Faehling and Ulrich Keilholz and Eckart Laack and Joachim von Pawel and Rudolf Huber and Nicolas Dickgreber and Z Voorendt Mark and Veronika S{\'a}rosi and Kumar Prabhash and Minish Jain and Srinivasan Venkatesan and Lalit Kr. Sharma and Hemant Dadhich and Rajnish Vasant Nagarkar and Amir Onn and Maya Gottfried and Solomon M Stemmer and Maria Rita Migliorino and Paolo Bidoli and Alessandra Bearz and Cesare Gridelli and Carlo Milandri and Marco Platania and Giovanni Luca Ceresoli and Giorgio Cruciani and Francisco Alberto Guti{\'e}rrez Delgado and Jos{\'e} Luis Gonzalez Perez and Gabriela Alvarado Luna and Othon Padilla Baca and J.G.J.V. Aerts and J Stigt and A. Dingemans and G.J.M. Herder and Steven J. M. Gans and Jorge Fernando Salas S{\'a}nchez and Renzo Luzgardo Alvarez Barreda and Wilbert Rodriguez Pantigoso and Osbert Luis Mejia Palomino and Piotr Jaśkiewicz and Andrzej Każarnowicz and Piotr Serwatowski and Aleksandra Szczęsna and Jacek Jassem and Vladimir Lubennikov and Nina A. Karaseva and Sergey Orlov and Yuri A. Ragulin and Pilar Garrido and Jos{\'e} Luis Gonz{\'a}lez Larriba and Carlos Enrique Camps and Rosario Garc{\'i}a Campelo and Pilar Lianes and M Sergio Cobo and E Felip and D. -J. Kim and Sang-We Kim and Joo-Hang Kim and Ji-Youn Han and Young Chul Kim and Chih-Hsin Yang and Te Chun Hsia and Yuh-Min Chen and Ying Huang Tsai and Gee-Chen Chang and Thomas Chang-yao Tsao and W Su and Ming-Shyan Huang and C. -H. Ho and Ruey-Kuen Hsieh and Oleksandr V. Popovych and Olga Ponomarova and I. K. Bondarenko and Iryna Polishchuk and Riyaz N H Shah and Sanka Mitra and James Spicer and Elizabeth Toy and Sanjaykumar Popat and Toby Talbot and Emma M Brown and Sunil Upadhyay and Yvonne Summers and Jayne S. Gurtler and Luis Rivera Meza and John P Thropay},
  booktitle={Annals of oncology : official journal of the European Society for Medical Oncology},
BACKGROUND Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy. PATIENTS AND METHODS Patients with relapsed/refractory disease following ≥1… CONTINUE READING
Twitter Mentions


Publications referenced by this paper.

An open label compassionate use programme of BIBW 2992/afatinib in advanced non-small cell lung cancer patients pre-treated with erlotinib or gefitinib in Korea

MK Choi, JY Lee, JY Hong
  • J Thorac Oncol
  • 2013

A phase I study of daily BIBW 2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel

JF Spicer, D Harris, J Ang
  • Ann Oncol 2008; 19(Suppl
  • 2008

Similar Papers

Loading similar papers…